Sarilumab vs placebo or usual care
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 0.99 [0.94, 1.05]7 studies · 2425 participantsModerate